Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ProMIS Neurosciences Inc. (PMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: PMN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.8
1 Year Target Price $5.8
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.95% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.76M USD | Price to earnings Ratio 4.34 | 1Y Target Price 5.8 |
Price to earnings Ratio 4.34 | 1Y Target Price 5.8 | ||
Volume (30-day avg) 3 | Beta -0.08 | 52 Weeks Range 0.38 - 2.22 | Updated Date 07/13/2025 |
52 Weeks Range 0.38 - 2.22 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -124.39% | Return on Equity (TTM) -19.56% |
Valuation
Trailing PE 4.34 | Forward PE - | Enterprise Value 4364507 | Price to Sales(TTM) 5168.19 |
Enterprise Value 4364507 | Price to Sales(TTM) 5168.19 | ||
Enterprise Value to Revenue 3868.08 | Enterprise Value to EBITDA -1.74 | Shares Outstanding 32689200 | Shares Floating 17658374 |
Shares Outstanding 32689200 | Shares Floating 17658374 | ||
Percent Insiders 27.61 | Percent Institutions 28.56 |
Upturn AI SWOT
ProMIS Neurosciences Inc.
Company Overview
History and Background
ProMIS Neurosciences Inc. is a biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
Core Business Areas
- Therapeutic Development: Research and development of antibody therapeutics targeting misfolded proteins in neurodegenerative diseases.
- Diagnostic Development: Development of diagnostic tools for early detection of neurodegenerative diseases.
Leadership and Structure
The leadership team includes Eugene Williams (Executive Chairman), Gail Farfel (CEO), and Johanne Kaplan (CFO). The company has a scientific advisory board comprised of leading experts in neurodegenerative diseases.
Top Products and Market Share
Key Offerings
- PMN310: PMN310 is ProMIS' lead antibody therapeutic candidate targeting toxic amyloid-beta oligomers in Alzheimer's disease. Currently in preclinical development. Competitors include Eisai/Biogen (Leqembi), Eli Lilly (donanemab), and Roche (gantenerumab), all targeting amyloid plaques, while PMN310 is aimed at oligomers. Market share data is not yet applicable as the product is not yet approved.
- ALS Programs: ProMIS has programs targeting TDP-43 misfolding in ALS. Preclinical stage. Competitors include Biogen (tofersen). Market share data is not yet applicable as the product is not yet approved.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by an aging population and a lack of effective treatments. Alzheimer's disease is a particularly significant unmet need.
Positioning
ProMIS is positioned as a developer of novel antibody therapeutics targeting toxic protein aggregates, a potential advantage over drugs that target plaques or other later-stage disease markers.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease treatments is estimated to be in the tens of billions of dollars annually. ProMIS aims to capture a share of this market with its oligomer-targeting approach.
Upturn SWOT Analysis
Strengths
- Novel oligomer-targeting technology
- Strong scientific advisory board
- Focus on high unmet medical needs
Weaknesses
- Early stage of development
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Breakthrough Therapy designation from regulatory agencies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Eisai (ESALY)
- Biogen (BIIB)
- Eli Lilly (LLY)
- Roche (RHHBY)
Competitive Landscape
ProMIS faces significant competition from larger pharmaceutical companies with more resources and established products in the neurodegenerative disease market. Its advantage lies in its novel oligomer-targeting technology.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is defined by advancement of its pipeline programs through preclinical and clinical development stages.
Future Projections: Future growth is contingent on successful clinical trials and potential commercialization or licensing of its antibody therapeutics.
Recent Initiatives: Recent initiatives include advancing PMN310 into clinical trials and expanding its pipeline of antibody therapeutics for other neurodegenerative diseases.
Summary
ProMIS Neurosciences is a high-risk, high-reward biotechnology company focused on innovative approaches to treating neurodegenerative diseases. Their novel targeting of toxic oligomers offers a potential advantage, but they face substantial challenges in terms of funding, clinical trial success, and competition from larger players. Positive clinical data or a major partnership is needed to increase its value. The company has no revenue and is dependent on raising funds. The science is strong.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProMIS Neurosciences Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2007-07-17 | CEO, President, Compliance Officer & Director Mr. Neil K. Warma M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.